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Abstract. The distribution process is an essential part of boosting the protability of
a company. Distribution process carried out the process of acquisition, purchase, stor-
age, distribution, transport, repackaging, re-labeling, documentation, and record-keeping
practices. The problems that occur in the validation process of each distribution process
in each party involved are not well registered and integrated with each other, so in the
complex drug distribution environment, the monitoring process becomes a necessity ev-
ery time more urgent and primary to reduce theft, prevent counterfeiting, and improve
eciency, synchronization, visibility, and safety. Providing good tracking of goods gives
consumers greater interest in the consumption of goods that meet certain ecological and
ethical standards and thus requires the quality of the goods consumed. In this thought, it
aims to discuss the best blockchain models for the drug distribution process. This research
is qualitative research. As a result, the model was introduced as a potential blockchain
model and could be applied in pharmaceutical companies in Indonesia.
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1. Introduction. Current technological developments will foster technological improve-
ments in the digital age, and this occurs in the distribution process that uses technology for
the process of data and information exchange. Distribution is the main driver of protabil-
ity in a company since it has a direct impact on logistics costs and customer experience
[1]. Distribution is an important activity in the integrated management of the product
supply chain. Distribution is one of the processes that occur in all industries, including
the pharmaceutical industry. Distribution process carried out the process of acquisition,
purchase, storage, distribution, transport, repackaging, re-labeling, documentation, and
record-keeping practices. In distribution, some people and entities are generally respon-
sible for handling, storing and distributing these products [1,2]. One of the distribution
processes in the pharmaceutical industry distributes drugs from the pharmaceutical in-
dustries to wholesalers, large merchants to hospitals or pharmacies, from pharmacies to
nal consumers (patients or the public) [3].
In this distribution process, the data must be integrated with each other. With this, you
can be closer to the concept of blockchain if we think about distributed data, data inte-
gration, more secure platforms, accounting books, databases, storage, data exchange and
connection of parts with real, unhandled data and ultimately trustworthy [4]. Blockchain
is a new technology that was originally introduced by a person or group of people called
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Satoshi Nakamoto in 2008 [5]. Blockchain is a distributed database that contains infor-
mation about all transactions that use peer-to-peer networks, hashing timestamp trans-
actions, in chains with markle trees that use hash-based proof of work that is carried out
consensually and digitally recorded in \blocks" and then linked cryptographically and
chronologically in \chains" using a set of mathematical or encryption algorithms [5,6],
thus forming records that cannot be changed [5,7]. The encryption technique guarantees
the user's ability to change only the part of the block he accesses, using private keys
and codes. Encryption also allows you to synchronize copies of the blockchain that are
distributed among the network bases stored in the ledger.
Figure 1. Blockchain [5]
In its development, blockchain technology began to clarify its inuence by providing
benets in economic, political, humanitarian, legal and other systems [8]. Blockchain has
the potential to change technological development and even has the ability to recongure
all aspects of society and its operations [7]. The concept of a blockchain with an open book
that is distributed, veried stakeholders (government and industry) will validate all drug
distribution transactions and documents to make the data more accurate and reliable.
The concept of blockchain is very acceptable to support the collaboration that occurs
between stakeholders in sectors close to the industry because of the values provided by
blockchain as \unchanged", \validated", \shared" and \open" [9]. Blockchain is close to
what we call an identity, each party needs a valid identity and recognition/approval from
government, industry and other related sectors. In supply chain management, especially
distribution in the pharmaceutical industry, there is a complexity of distribution in the
participation of stakeholders, including government institutions, hospitals, clinics, drug
manufacturers, drug distributors, pharmaceutical chains, retailers, research organizations
[10]. The process of distribution to consumers should be able to guarantee or guarantee
that medicines are well received, of high quality and according to needs [11-13]. Blockchain
technology will help pharmaceutical companies minimize their knowledge of operational
results in the development of medicines for the process of distributing medicines to nal
consumers [14].
In the system in Indonesia, the distribution process has aspects that must be complied
with or carried out in accordance with the guidelines for a good distribution of drug (C-
DOB) based on the Head of BPOM Regulation number HK 03.1.34.11.12.7542 in 2012,
which include quality management, organization, management and personnel, buildings
and equipment, operations, self-inspection, complaints of drugs and/or materials for re-
turned drugs, suspected falsication and withdrawal, transportation, contract facilities
and documentation [15,16]. This guideline must be carried out by all parties in the drug
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distribution chain. Indonesia in realizing the vision and mission of national industrial
development to improve public health, the pharmaceutical industry has several problems
that occur in the distribution of medicines, among others: data of drugs not yet admin-
istered registered in BPOM (+=  20,000 types) and data from uncontrolled distributors
available (+=  2821 PBF) [17], BPOM in 2013 received 71 drug circulation ndings with
a value of Rp. 5.67 thousand million, in 2014 the ndings reached 3,656 items with a
value of Rp. 31.6 billion, in 2015 up to 3,671 items with a value of Rp. 20.8 billion, and in
2016 the February-March 2016 period found up to 4,441 items with values that reached
Rp. 49.8 billion [18]. This problem is because the handling of drug data has not been
done well; there are still many distribution systems through unocial distributors or those
not listed in BPOM [19]. Another violation that occurs in the sale of medicines is the
sale of counterfeit medicines and expired drugs in the pharmacy, the sale of drugs that
contain narcotics, psychotropics and hard drugs that are not by the rules determined by
the government [20].
The problems that occur due to the system are not integrated and the lack of a sys-
tematic follow-up/follow-up process in the process of distribution of complex medicines
that results in not recognizing the data of medicines and the uncontrolled distribution of
medicines in the market [21,22]. The validation process of each distribution process in each
party involved is not registered and is well integrated with each other, so that in a complex
environment of drug distribution, the monitoring process becomes an increasingly urgent
and primary need to be able to increase the theft reduction, prevent counterfeiting and in-
crease eciency, synchronization, visibility and security [23,24]. Providing good tracking
of goods gives consumers greater interest in the consumption of goods that meet certain
ecological and ethical standards and thus requires the quality of the goods consumed.
Figure 2. Pharmacy distribution model with blockchain
This research proposes the process of identifying the drug distribution process that
occurs with each party involved in the network by validating the transactions that oc-
cur. The transactions are carried out from the pharmaceutical industry that produces
medicines, then requests medicines from the wholesalers, then to hospitals or pharmacies,
at the hands of the nal consumers who need it. Based on the background, blockchain
represents a framework that can be used for drug distribution problems to cope with
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the circulation of counterfeit or illegal drugs. In this study, using the qualitative one to
answer the question \How can the blockchain framework be implemented to eradicate the
circulation of counterfeit or illegal drugs in Indonesia?". In addition, the purpose of this
study can contribute to responding to problems that occur due to integrated data, data
transparency and validated data to provide certainty about the reliability of drug distri-
bution data in order to minimize information incorrect that irresponsible parties may use
incorrectly. With the application of the blockchain concept, it is considered appropriate
and good to meet each of your needs in the drug distribution transaction process.
2. Research Methodology. In this case, the research steps carried out to develop a
model of drug distribution model in the pharmaceutical industry were explained. The
following is the research methodology performed in this study in Figure 3.
Figure 3. Research methodology
2.1. Research background study. The initial process is carried out, the researchers
look for phenomena from the problems that occur in the distribution process with the
problem that the drug data has not been administered in BPOM and the distributor data
is not well managed [17], the discovery of the distribution of illegal drugs in the drug
distribution chain [18]. There are still many distribution systems through unocial or
unregistered distributors, violations in the sale of drugs that have expired in pharmacies
[19], and the sale of medicines that are not in accordance with the rules established by
the government [20]. This problem has become the need for researchers to nd a model
framework that has not yet been applied.
2.2. Problem identication. This study identies the problems that occur when ob-
taining large quantities of illegal or false drugs in the drug distribution process. Coun-
terfeit or illegal drugs are a form of action that is very harmful to those interested in
distribution because it makes the product sell less and even reduces consumer condence
in the product. Where it was expected that the role of all stakeholders could stop the
process. In this study the process of nding methods, frameworks, and ideas for verifying
drugs that can be veried and improved according to instructions in the drug distribution
process is carried out.
2.3. Research objectives. This study explains the purpose of this study specically
and solves the problems that occur. The purpose of this study is to build a distribution
model to provide open data and information that can be audited, valid and reliable so
that the proven portfolio and medication credentials are original and useful medications
using this blockchain technology model.
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2.4. Literature review. A literature review was conducted to help researchers obtain a
review of the literature that is appropriate and supports this research. The review of the
literature in this study focuses on the implementation of blockchain in the pharmaceutical
industry, so it is the basis of the models built for the pharmaceutical industry.
2.5. Business process model for pharmaceutical. The development of business pro-
cesses is carried out, the researcher investigates and proposes a process model that is
compatible with the pharmaceutical industry. Then, the researcher decided on the best
solution to design models. The business process model for the pharmaceutical industry
was obtained from the four largest pharmaceutical companies in Indonesia involved in the
survey to reect the general business model.
2.6. Blockchain pharmaceutical model design. At this stage, draw the entire process
in the drug distribution process using blockchain identifying each entity involved in each
block.
2.7. Model for distribution drug in pharmaceutical industry. The model will de-
scribe the framework of each thing showing the integration of data so that each interested
party can interact with each other. Within this framework, the general transaction pro-
cess of all parties can be recorded appropriately and indelibly so that the data is always
valid and veried for each transaction block. The data may also be used by other parties
that have been veried following their respective interests. So that the drug distribution
transaction process that leaves the drug factory to the nal consumer can be appropriately
registered and validated. The drug distribution process carried out in the pharmacy in-
cludes the process of receiving orders, acquiring orders, making shipping invoices, sending
goods. This process is carried out between the pharmaceutical industry to wholesalers and
wholesalers to retailers (hospitals or pharmacies) that are controlled by aspects of CDOB
[16], that has been established by the government and the nal process for consumers
to obtain the necessary medications in drug stores or health services. The application
of blockchain technology is the most critical part of this process, where each party can
make transactions between peers to be validated and integrated so that each party can
access the data according to the interests of the example. Consumers can guarantee that
the purchased medication is the correct medication, reasonable, quality, and following the
provisions of the doctor.
2.8. Introduction to pharmaceutical industries. Based on the research, conrming
that the model designed can be applied in all pharmaceutical industries in Indonesia. In
the validation of the model made by respondents, that is the pharmaceutical industry that
has the highest level of sales in Indonesia, there are four companies selected. In carrying
out this socialization, it is expected that this model can be generalized throughout the
pharmaceutical industry in Indonesia.
3. Result and Discussion. We describe the process in a business process value chain
that is at the center of the drug distribution process in the pharmaceutical industry. This
value chain describes the entire process that directs the use of the blockchain concept.
The distribution process of the pharmaceutical drug business model with blockchain
illustrates the integration of the transaction processes in each stakeholder that occurs
within the blockchain technology supported by the CDOB aspects. That can be shown
in Figure 4. Due to this base, blockchain is very suitable to be applied in the industrial
sector, especially in the distribution process, so that the interested parties can keep track
of the drug distribution transactions. The blockchain model developed records and inte-
grates all drug distribution activities from collaboration between government, industry,
pharmaceutical wholesalers, community service facilities (hospitals, pharmacies) and end
consumers. Based on what is needed in the pharmaceutical world, this research creates
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Figure 4. Business model distribution of pharmaceutical drugs with
blockchain in Indonesia
Figure 5. Transaction model distribution of pharmaceutical drugs with blockchain
a new blockchain model for the distribution process of the pharmaceutical industry in
Indonesia. The processing of the transaction will be in the form of blocks related to each
other occuring in the validation process by the participants in the network so that the
data becomes more reliable. This can be seen in Figure 5.
4. Conclusion. Model is designed based on the core business processes of the largest
pharmaceutical companies in Indonesia. In this model, the integration of data, validated
data and centralized information carried by blockchain technology is illustrated. In this
case, interested stakeholders can access the same data and the data can be validated in
real time, which provides a condition for data that is kept updated, validated, veried,
accurate and can be tracked well.
In the application of this blockchain, a solution is provided to the problem of the
circulation of counterfeit drugs, which is a common problem that occurs in various parts
of the world. This happens by not validating information, integrating the information to
provide an opportunity for evil parties who are not interested in spreading fake drugs.
For this reason, this research proposes an model that is based on blockchain technology
that oers data integration, data tracking. All this is reected in this very important
and good concept for the pharmaceutical industry to maintain the quality of the drugs
that are in circulation and support the government in the eradication and control of the
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distribution of medicines to consumers. With this, you can provide a healthy and good
life for the community.
This research has implications for this model that can help interested parties (gov-
ernment, pharmaceutical wholesalers, pharmacies, hospitals) to obtain integrated data,
validated data according to their individual needs. This model can also help strengthen
the government in controlling the distribution process that occurs in the pharmaceuti-
cal market. The pharmaceutical industry can see the process of drug transactions that
occur in the distribution process. Consumers can verify data on medications purchased
at a pharmacy or hospital. In the future, blockchain technology should be designed in a
detailed model for each process that takes place and a prototype is implemented to pro-
vide evidence of the integration of data between stakeholders regarding the distribution
of medicines.
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